JP2025516633A - 併用療法においてcd27に結合する能力を有する結合剤 - Google Patents
併用療法においてcd27に結合する能力を有する結合剤 Download PDFInfo
- Publication number
- JP2025516633A JP2025516633A JP2024566508A JP2024566508A JP2025516633A JP 2025516633 A JP2025516633 A JP 2025516633A JP 2024566508 A JP2024566508 A JP 2024566508A JP 2024566508 A JP2024566508 A JP 2024566508A JP 2025516633 A JP2025516633 A JP 2025516633A
- Authority
- JP
- Japan
- Prior art keywords
- region
- seq
- binding
- amino acid
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341406P | 2022-05-12 | 2022-05-12 | |
| US63/341,406 | 2022-05-12 | ||
| PCT/EP2023/062798 WO2023218051A1 (en) | 2022-05-12 | 2023-05-12 | Binding agents capable of binding to cd27 in combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516633A true JP2025516633A (ja) | 2025-05-30 |
| JP2025516633A5 JP2025516633A5 (cg-RX-API-DMAC7.html) | 2026-05-18 |
Family
ID=86378569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566508A Pending JP2025516633A (ja) | 2022-05-12 | 2023-05-12 | 併用療法においてcd27に結合する能力を有する結合剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250325643A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4522275A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516633A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119365215A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023269546A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3252821A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316632A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202409090A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023218051A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| JP6002659B2 (ja) | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトcd27に結合する抗体およびその使用 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CA2804550C (en) | 2010-07-09 | 2021-01-05 | Bionovion Holding B.V. | Agonistic antibody to cd27 |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| KR20150058236A (ko) | 2012-08-20 | 2015-05-28 | 글리크닉 인코포레이티드 | 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자 |
| MX387324B (es) | 2013-01-10 | 2025-03-18 | Genmab Bv | Variantes de regiones fc de igg1 de humano y usos de las mismas. |
| CN106459165B (zh) | 2014-04-01 | 2021-04-20 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| JP2017513481A (ja) | 2014-04-16 | 2017-06-01 | ユーシービー バイオファルマ エスピーアールエル | 多量体Fcタンパク質 |
| WO2016145085A2 (en) | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| BR112019000512A2 (pt) * | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| BR112019015900A2 (pt) | 2017-02-10 | 2020-04-07 | Genmab B.V. | polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição |
| CA3074317C (en) * | 2017-08-25 | 2024-06-18 | Janssen Biotech, Inc. | Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them |
| US12649798B2 (en) | 2018-01-24 | 2026-06-09 | Genmab B.V. | Polypeptide variants and uses thereof |
| EP3774903A1 (en) | 2018-04-04 | 2021-02-17 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
| AU2022233547A1 (en) * | 2021-03-09 | 2023-09-28 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in therapy |
| WO2023285552A1 (en) * | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
-
2023
- 2023-05-12 TW TW112117781A patent/TW202409090A/zh unknown
- 2023-05-12 EP EP23723603.9A patent/EP4522275A1/en active Pending
- 2023-05-12 JP JP2024566508A patent/JP2025516633A/ja active Pending
- 2023-05-12 IL IL316632A patent/IL316632A/en unknown
- 2023-05-12 CA CA3252821A patent/CA3252821A1/en active Pending
- 2023-05-12 WO PCT/EP2023/062798 patent/WO2023218051A1/en not_active Ceased
- 2023-05-12 AU AU2023269546A patent/AU2023269546A1/en active Pending
- 2023-05-12 US US18/861,928 patent/US20250325643A1/en active Pending
- 2023-05-12 CN CN202380046573.5A patent/CN119365215A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202409090A (zh) | 2024-03-01 |
| CA3252821A1 (en) | 2023-11-16 |
| CN119365215A (zh) | 2025-01-24 |
| IL316632A (en) | 2024-12-01 |
| EP4522275A1 (en) | 2025-03-19 |
| US20250325643A1 (en) | 2025-10-23 |
| AU2023269546A1 (en) | 2024-11-14 |
| WO2023218051A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018309339B2 (en) | Binding agents binding to PD-L1 and CD137 and use thereof | |
| JP7527281B2 (ja) | 抗体製剤 | |
| US20250289899A1 (en) | Antibodies capable of binding to cd27, variants thereof and uses thereof | |
| US20240327544A1 (en) | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer | |
| JP2026516142A (ja) | Ox40に結合することができる抗体、そのバリアント、およびその使用 | |
| CN118055950A (zh) | 能够结合cd27的抗体、其变体及其用途 | |
| US20250325643A1 (en) | Binding agents capable of binding to cd27 in combination therapy | |
| JP2025516631A (ja) | 併用療法においてcd27に結合する能力を有する結合剤 | |
| HK40110711A (en) | Antibodies capable of binding to cd27, variants thereof and uses thereof | |
| HK40061281A (en) | Antibody formulation | |
| EA052790B1 (ru) | Биспецифическое антитело, связывающее pd-l1 и cd137, его получение и применение в медицине |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260508 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260508 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260723 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260807 |